Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 383,984
  • Shares Outstanding, K 149,410
  • Annual Sales, $ 53,450 K
  • Annual Income, $ -168,840 K
  • 60-Month Beta 2.30
  • Price/Sales 6.83
  • Price/Cash Flow N/A
  • Price/Book 33.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.31
  • Number of Estimates 6
  • High Estimate -0.12
  • Low Estimate -0.40
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -3.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.27 +6.17%
on 03/01/19
6.13 -60.65%
on 02/25/19
-3.32 (-57.94%)
since 02/22/19
3-Month
2.27 +6.17%
on 03/01/19
6.13 -60.65%
on 02/25/19
-1.53 (-38.83%)
since 12/21/18
52-Week
2.27 +6.17%
on 03/01/19
13.41 -82.03%
on 03/26/18
-9.75 (-80.18%)
since 03/22/18

Most Recent Stories

More News
Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

IMGN : 2.41 (-6.23%)
ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN : 2.41 (-6.23%)
SmarTrend Watching for Potential Pullback in Shares of Immunogen Inc After 4.01% Gain

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $2.80 to a high of $2.85. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $2.78...

IMGN : 2.41 (-6.23%)
Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

CELG : 88.15 (-1.65%)
NITE : 25.29 (-0.08%)
IMGN : 2.41 (-6.23%)
REGN : 391.80 (-2.68%)
BIIB : 216.71 (-4.48%)
Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks

Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.

CELG : 88.15 (-1.65%)
MRK : 82.29 (-0.80%)
IMGN : 2.41 (-6.23%)
RHHBY : 33.7600 (-1.06%)
SmarTrend Watching for Potential Rebound in Shares of Immunogen Inc After 47.35% Loss

Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $2.31 to a high of $2.50. Yesterday, the shares fell 47.4%, which took the trading range below the 3-day low of $4.52...

IMGN : 2.41 (-6.23%)
ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer

--Efficacy Signal Seen in High Folate Receptor Alpha Patients; Additional Analyses to be Conducted

IMGN : 2.41 (-6.23%)
ImmunoGen Announces Multiple Presentations at AACR Annual Meeting

--First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers

IMGN : 2.41 (-6.23%)
Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Apple Inc. (NASDAQ:AAPL), United...

UAL : 79.63 (-1.69%)
AAPL : 191.05 (-2.07%)
GVA : 43.11 (-6.04%)
CBAY : 11.93 (-7.66%)
IMGN : 2.41 (-6.23%)
FTK : 3.15 (-2.78%)
Biotech Risers You Can't Miss

HENDERSON, NV / ACCESSWIRE / February 14, 2019 / The biotech market has been providing investors with several profit opportunities so far this year. Below are a few companies you should research right...

VKTX : 8.26 (-10.99%)
CRON : 19.23 (-6.38%)
IMGN : 2.41 (-6.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade IMGN with:

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 2.70
1st Resistance Point 2.55
Last Price 2.41
1st Support Level 2.33
2nd Support Level 2.26

See More

52-Week High 13.41
Fibonacci 61.8% 9.15
Fibonacci 50% 7.84
Fibonacci 38.2% 6.53
Last Price 2.41
52-Week Low 2.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar